LOS ANGELES -- AIDS Healthcare Foundation (AHF) the largest U.S.-based AIDS organization with free AIDS treatment clinics in the United States, Africa, Central America and Asia, welcomed the news that the United States Food and Drug Administration (FDA) has approved generic AIDS drugs produced by South Africas Aspen Pharmacare. The move makes the pharmaceutical manufacturer the first in the world to receive approval from the U.S. government agency for its generic anti-retroviral drugs to fight AIDS. The FDAs action also clears the way for Aspens far less costly AIDS drugs -- specifically, its combination of lamivudine/zidovudine and nevirapine tablets -- to be utilized in Presidents Bushs ambitious $15 billion, 5-year Presidents Emergency Plan For AIDS Relief (PEPFAR). The President had made FDA approval a requirement of any generic medicines that PEPFAR uses in its global treatment efforts.
Todays FDAs approval of Aspens generic life-saving AIDS drugs could truly save hundreds of thousands of lives, said Michael Weinstein, president of AIDS Healthcare Foundation. This approval now allows PEPFAR to utilize Aspens generic AIDS drugs in its global treatment efforts to get two million people in treatment. We strongly urge the President and PEPFAR officials to quickly incorporate these effective, yet far less costly anti-retroviral drugs into PEPFARs treatment programs in Africa and the Caribbean. We believe that three times as many people can be treated -- and three times as many lives saved -- by using safe, effective and far cheaper generic AIDS drugs.
The approval is for Aspens generic equivalent of the most widely used triple cocktail combination of lamivudine/zidovudine (branded as GSKs Combivir) and nevirapine (branded as Boehringer Ingelheims Viramune) tablets in conventional adult dosages.
The FDA approval now means that Aspen has become the first accredited generic supplier to have access to the Presidents Emergency Plan for Aids Relief fund.
Source: AIDS Healthcare Foundation
Weekly Rounds: Four Years of COVID-19, AORN 2024 Conference Coverage, and More
March 18th 2024Here are 5 highlights from Infection Control Today®'s (ICT®’s) wide-ranging coverage of the infection prevention and control world. Everything from interviews with known opinion leaders to the news that infection preventionists and other health care professionals can use on their jobs.
Four Years After COVID-19: What Has the Infection Prevention Community Learned?
March 15th 2024Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?
Could Empathy Help Overcome Vaccine Hesitancy?
March 14th 2024Research findings reveal that correcting misinformation about vaccination can remarkably transform individuals' attitudes toward it. This highlights the crucial role of accurate information in making informed decisions about vaccination.
Empowering Safety: A Massachusetts General Hospital Team Is Pushing for Smoke-Free ORs
March 13th 2024At the AORN’s International Surgical Conference & Expo 2024, a team from Massachusetts General Hospital (MGH) showcased their transformative project, "Becoming Smoke-Free in the OR." This initiative underscored the critical need for smoke evacuation in surgical settings.
Hand Hygiene Practices in the Operating Room: A Collaborative Endeavor
March 13th 2024As explained on a poster at AORN 2024, perioperative nurses and infection preventionists unite in a proactive campaign to elevate hand hygiene within the operating room, resulting in improved adherence, decreased infections, and fortified patient outcomes.